Replies to post #352337 on Amarin Corp Plc (AMRN)

[mrmainstreet]

So we have now dropped back under 80k. This is a massacre. The company is going backwards.

[fsulevine]

Ugh… but thank you for the info Raf!

[Jasbg]

raf, Thanks again. Would have been a nicer job - if we were not loosing to generics - all the time:)

Hikma/Reddy obviously don't fear the infringement case - looking at the numbers.

[circuitcity]

Thanks for the info, so we know exactly how amrn is doing.

[Invest83838]

Thank You Corrupt USA Patent Court System

[Examiner77]

Thxx for the numbers Raf!

[ralphey]

Na there is no infringement occurring because

1.) The recognition to treat trigs >500 just occurred to most docs

2.) The trig> 500 market is so much greater than the CAD market

3.) HIKMA and Dr. Reddy are pouring millions of dollars into educating physicians to treat trigs > 500

4.) EPA works so much better then DHD/EPA top lower trigs

[circuitcity]

I just can’t understand why don’t amrn launch their own generic, they will dominate current O3 market easily, taking over lovaza market share with min marketing spendse, and their rev will be an easy billion per year. This is just crazy watching them doing nothing every week, and keeping hundreds rep in staff. Best job!

[rafunrafun]

Scripts for week ending August 27, 2021

Overall drug TRx are -0.1% w/w

Vascepa
TRx 79,721; +0.0% (+12) w/w; -12.1% y/y
NRx 36,134; +3.5% (+1,234) w/w; -13.2% y/y
Ref 43,586; -2.7% (-1,222) w/w; -11.2% y/y

Lovaza (Generic & Brand)
TRx 61,572; -0 6% (-350) w/w; -2.3% y/y
NRx 30,153; +0.6% (+170) w/w; -2.5% y/y
Ref 31,419; -1.6% (-519) w/w; -2.1% y/y

Generic Vascepa
TRx 16,756; +1.3% (+216) w/w; As % of total V: 17.4%
NRx 9,672; +6.4% (+583) w/w; As % of total V: 21.1%
Ref 7,084; -4.9% (-367) w/w; As % of total V: 14.0%

Generic Vascepa by Manufacturer
Hikma TRx 11,526 (-493); Generic share 68.8%; Total V share 11.9%
Reddy TRx 5,230 (+709); Generic share 31.2%; Total V share 5.4%